Talimogene laherparepvec (T-VEC) as cancer immunotherapy.

• Autores: F.J. Kohlhapp, A. Zloza, H.L. Kaufman
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 51, Nº. 9, 2015, págs. 549-558
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Talimogene laherparepvec (T-VEC) is the first-in-class oncolytic virus immunotherapy for the treatment of cancer and was generated from an attenuated, recombinant herpes simplex virus. T-VEC has demonstrated therapeutic activity in melanoma patients and is being tested in a number of other cancers alone and in combination with standard cancer therapeutics and other immunotherapy agents. This review will discuss the current landscape of melanoma, the construction and application of T-VEC for melanoma along with other indications for T-VEC, as well as highlight some of the novel challenges with oncolytic virus immunotherapy as it enters into clinical practice.